Medication info
Durotel 80/10 mg Tablet

Durotel 80/10 mg Tablet

Prescription medicationTabletOral
Ingredient · strength
Telmisartan›80mg / 1 tabletRosuvastatin Calcium›10.4mg / 1 tablet
Manufacturer / importer
Widers Pharmaceutical Co., Ltd.
Appearance
Light orange oval film-coated tablet
Packaging
30 tablets/box [10 tablets/PTP x 3]
Approval status
Active

MFDS item code 202104526 · Approved 2021.06.14

Summary

Main use
Treatment of hypertension and dyslipidemia, and reduction of atherosclerosis progression and cardiovascular disease risk
Who takes it
Adults
Adult dose
This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, telmisartan and rosuvastatin. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose is 40 mg of telmisartan orally once daily; 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to 80 mg once daily. When this medicine is administered in combination with a thiazide diuretic such as hydrochlorothiazide, it has an additional blood pressure-lowering effect. When the dose is increased, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after starting treatment. 2. Reduction of cardiovascular risk Adults: The recommended dose of this medicine is 80 mg orally once daily. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg has not been established. When starting treatment with this medicine to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive therapy may be necessary. 3. Patients with hepatic impairment Use with caution in patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is sufficient for most patients. Adjust the maintenance dose as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response; the dose may be increased up to a maximum of 20 milligrams per day. 2. Older adults: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering this medicine 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking telmisartan and rosuvastatin concomitantly may switch to this medicine (a fixed-dose combination with the same amounts of each active ingredient) for convenience.

Ingredients

Manufacturer
Widers Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension and dyslipidemia, and reduction of atherosclerosis progression and cardiovascular disease risk

  • Essential hypertension
  • coronary artery disease
  • peripheral artery disease
  • stroke
  • transient ischemic attacks
  • clinical evidence of end-organ damage
  • high-risk diabetes
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed-type hyperlipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
View approved original text

This medication is indicated for patients who require concomitant therapy with telmisartan and rosuvastatin. Telmisartan primarily helps treat essential hypertension and reduce cardiovascular disease risk. It is particularly effective in reducing the risk of myocardial infarction, stroke, and mortality from cardiovascular diseases in high-risk patients aged 55 years and older. Rosuvastatin is used for the treatment of hypercholesterolemia and mixed-type hyperlipidemia, acting as an adjunct to diet when control through diet and exercise is inadequate. Additionally, it lowers the total cholesterol and LDL cholesterol levels in hypercholesterolemic patients, helping to delay the progression of atherosclerosis and reduce the risk of cardiovascular disease. Therefore, this medication is used to manage both hypertension and hyperlipidemia simultaneously to reduce cardiovascular disease risk.

How to take

Adult dose

This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, telmisartan and rosuvastatin. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose is 40 mg of telmisartan orally once daily; 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to 80 mg once daily. When this medicine is administered in combination with a thiazide diuretic such as hydrochlorothiazide, it has an additional blood pressure-lowering effect. When the dose is increased, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after starting treatment. 2. Reduction of cardiovascular risk Adults: The recommended dose of this medicine is 80 mg orally once daily. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg has not been established. When starting treatment with this medicine to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive therapy may be necessary. 3. Patients with hepatic impairment Use with caution in patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is sufficient for most patients. Adjust the maintenance dose as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response; the dose may be increased up to a maximum of 20 milligrams per day. 2. Older adults: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering this medicine 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking telmisartan and rosuvastatin concomitantly may switch to this medicine (a fixed-dose combination with the same amounts of each active ingredient) for convenience.

Precautions

This medication can cause serious harm to the fetus and newborn during pregnancy, so it should be discontinued immediately if pregnancy is confirmed. Individuals allergic to this medication or its components, pregnant women or women of childbearing potential, and nursing mothers should not use this medication. Patients with severe liver impairment or biliary excretion issues, unexplained increases in liver enzyme levels, myopathy, hereditary angioedema, and severe renal impairment should not take this medication. Particularly, patients with diabetes or moderate to severe renal impairment should not take this medication together with certain other drugs. Elderly patients, patients with high serum potassium levels, those with slightly compromised liver function, and patients with heart or vascular diseases should use this medication cautiously and require regular monitoring during treatment. This medication may cause muscle-related side effects such as myalgia or muscle weakness, so patients should consult a doctor immediately if they experience any abnormal muscle symptoms during treatment. Additionally, liver function abnormalities may occur, so regular liver enzyme tests should be conducted, and if liver function worsens significantly, the medication should be discontinued. This medication may interact with other drugs, so patients taking other medications should inform their doctor or pharmacist. Caution is needed for dizziness or drowsiness when driving or operating machinery. In case of overdose, symptoms such as hypotension, dizziness, and acute renal failure may occur, necessitating immediate medical attention. It is safest for children, pregnant women, and nursing mothers not to take this medication. Regular blood tests and symptom observations are required during the course of treatment, and immediate consultation with healthcare professionals is necessary if any abnormal symptoms occur.

Side effects

Elevated ALT, elevated AST, elevated blood creatine phosphokinase (CPK), dizziness, pruritus, dyspepsia, oral paresthesia, musculoskeletal rigidity, acne, nasopharyngitis, dysuria, rhinitis, oropharyngeal discomfort, lung disease, unspecified gastrointestinal disorder, benign gastrointestinal neoplasm, hemorrhoids, skeletal pain, osteoporosis, sensory loss, movement disorders, atherosclerosis, frequent urination, tinnitus, hearing loss, halitosis, fatty liver, upper respiratory tract infection, urinary tract infection, sepsis, anemia, thrombocytopenia, eosinophilia, hypersensitivity, anaphylactic reaction, hyperkalemia, hypoglycemia, depression, insomnia, anxiety, syncope, visual disturbances, bradycardia, tachycardia, hypotension, orthostatic hypotension, dyspnea, abdominal pain, diarrhea, abdominal distension, vomiting, abdominal discomfort, dry mouth, abnormal liver function, liver dysfunction, increased sweating, rash, erythema, angioedema, drug rash, toxic skin rash, eczema, urticaria, myalgia, lumbago, muscle cramps, arthralgia, limb pain, tendinopathy, acute renal failure, chest pain, weakness, influenza-like illness, increased blood creatinine, increased blood uric acid, elevated liver enzymes, increased blood CK, decreased hemoglobin, headache, facial spasms, sensory disturbances, paralysis, cough, hyperventilation, pneumonia, flushing, erectile dysfunction, loss of appetite, arrhythmia, weakness, edema, decreased libido, facial swelling, alopecia, conjunctivitis, tinnitus, petechiae, polyneuropathy, amnesia, peripheral neuropathy, diarrhea, thrombocytopenia, jaundice, hepatitis, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, sexual dysfunction, gynecomastia, liver failure, cognitive impairment, severe myasthenia gravis, ocular myasthenia gravis, constipation, nausea, pancreatitis, pruritus, rash, urticaria, myopathy, rhabdomyolysis, weakness, myalgia, increased CK, abnormal liver function tests, syncope, generalized pain, muscle cramps, gout, erectile dysfunction, thrombocytopenia, increased blood creatinine, acute renal failure, oliguria

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it should be stored in a tightly sealed container. It is also recommended to store the medication at room temperature, between 1°C and 30°C, rather than in extremely hot or cold conditions.

Appearance and packaging

Appearance

Light orange oval film-coated tablet

Package unit

30 tablets/box [10 tablets/PTP x 3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.